Abstract:Background: The equine infectious anemia virus (EIAV) is a lentivirus of the Retrovirus family, which causes persistent infection in horses often characterized by recurrent episodes of high fever. It has a similar morphology and life cycle to the human immunodeficiency virus (HIV). Its transmembrane glycoprotein, gp45 (analogous to gp41 in HIV), mediates membrane fusion during the infection. However, the post-fusion conformation of EIAV gp45 has not yet been determined. EIAV is the first member of the lentiviruses for which an effective vaccine has been successfully developed. The attenuated vaccine strain, FDDV, has been produced from a pathogenic strain by a series of passages in donkey dermal cells. We have previously reported that a V/I505T mutation in gp45, in combination with other mutations in gp90, may potentially contribute to the success of the vaccine strain. To this end, we now report on our structural and biochemical studies of the gp45 protein from both wide type and vaccine strain, providing a valuable structural model for the advancement of the EIAV vaccine.Results: We resolved crystal structures of the ecto-domain of gp45 from both the wild-type EIAV and the vaccine strain FDDV. We found that the V/I505T mutation in gp45 was located in a highly conserved d position within the heptad repeat, which protruded into a 3-fold symmetry axis within the six-helix bundle. Our crystal structure analyses revealed a shift of a hydrophobic to hydrophilic interaction due to this specific mutation, and further biochemical and virological studies confirmed that the mutation reduced the overall stability of the six-helix bundle in post-fusion conformation. Moreover, we found that altering the temperatures drastically affected the viral infectivity.Conclusions: Our high-resolution crystal structures of gp45 exhibited high conservation between the gp45/gp41 structures of lentiviruses. In addition, a hydrophobic to hydrophilic interaction change in the EIAV vaccine strain was found to modulate the stability and thermal-sensitivity of the overall gp45 structure. Our observations suggest that lowering the stability of the six-helix bundle (post-fusion), which may stabilizes the pre-fusion conformation, might be one of the reasons of acquired dominance for FDDV in viral attenuation.

Broader HIV-1 Neutralizing Antibody Responses Induced by Envelope Glycoprotein Mutants Based on the EIAV Attenuated Vaccine

Amino Acid Mutations in the Env Gp90 Protein That Modify N-linked Glycosylation of the Chinese EIAV Vaccine Strain Enhance Resistance to Neutralizing Antibodies.

Comparison of Antibody Immune responses to different HIV-1 Envelope Glycoprotein Mutants.

Amino Acid Mutations of the Infectious Clone from Chinese EIAV Attenuated Vaccine Resulted in Reversion of Virulence.

Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV

A Pilot Study on an Attenuated Chinese EIAV Vaccine Inducing Broadly Neutralizing Antibodies

Modified HIV Envelope Proteins with Enhanced Binding to Neutralizing Monoclonal Antibodies

Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination.

Enhancement of Human Immunodeficiency Virus Type 1 Infection by Antisera to Peptides from the Envelope Glycoproteins Gp120/gp41.

Deglycosylation of Hiv-1 Ae Gp140 Enhances the Capacity to Elicit Neutralizing Antibodies Against the Heterologous Hiv-1 Clade

Amino Acid Changes in the HIV-1 Gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity

Epitope-focused Immunogens Against the CD4-binding Site of HIV-1 Envelope Protein Induce Neutralizing Antibodies Against Auto- and Heterologous Viruses

Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity Against Membrane-Proximal External Region

Structural and Biochemical Insights into the V/I505T Mutation Found in the EIAV Gp45 Vaccine Strain

Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens

Construction of an Infectious Clone Within the V3 Region of Gp90 Surface Protein of EIAV by N-glycosylation Revers-mutations

Broad HIV-1 Neutralizing Antibody Response Induced by Heterologous Gp140/gp145 DNA Prime-Vaccinia Boost Immunization

Single N277A Substitution in C2 of Simian Immunodeficiency Virus Envelope Influences Vaccine-Elicited CD4i Neutralizing and Anti-V2 Antibody Responses.

Amino acid substitution of the membrane-proximal external region alter neutralization sensitivity in a chronic HIV-1 clade B infected patient

Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient with Broadly Neutralizing Activity.

Exploration of a Sequential Gp140-Gp145 Immunization Regimen with Heterologous Envs to Induce a Protective Cross-Reactive HIV Neutralizing Antibody Response In Non-human Primates